API Citicoline Powder Nootropics Cytidine Diphosphate-Choline (CDP-Choline) CAS 33818-15-4

Citicoline is a multimodal agent that has demonstrated neuroprotective and neuroregenerative effects in various experimental and clinical disorders of the central nervous system, including acute and chronic cerebral ischemia, cerebral hemorrhage, and global cerebral hypoxia. It provides neuroprotection by attenuating glutamate excitotoxicity, oxidative stress, apoptosis, and blood-brain barrier dysfunction.

In recent years, in addition to being used in brain surgery and traumatic brain injury, it is also used in the auxiliary treatment of function and consciousness, tremor paralysis, tinnitus and nervous deafness, glaucoma and amblyopia caused by acute injury of the central nervous system.

Citicoline may also act as an adjuvant therapy and prevent cognitive decline and other neurological complications associated with   disease 2019.

CDPC can be administered intravenously, intramuscularly or orally: after administration, citicoline sodium is catabolized relatively quickly and is the source of choline in the blood. After oral administration, citicoline sodium is rapidly absorbed and then hydrolyzed into choline and cytidine in the intestinal wall and liver; thus, in addition to providing metabolic precursors of phospholipids, it also enters the synthesis pathways of nucleic acids, proteins and acetylcholine.

Today, citicoline is available as an oral, intravenous infusion, intramuscular injection, and eye drops.